Dengue is the world's most prevalent and important arboviral disease. More than 50% of the
world's population lives at daily risk of infection and it is estimated more than 95 million …

Dengue is a highly endemic infectious disease of the tropical countries and is rapidly
becoming a global burden. It is caused by any of the 4 serotypes of dengue virus and is …

Dengue virus poses a major threat to global public health: two-thirds of the world's
population is now at risk from infection by this mosquito-borne virus. Dengue virus causes a …

Background Roughly half the world's population live in dengue-endemic countries, but no
vaccine is licensed. We investigated the efficacy of a recombinant, live, attenuated …

The first approved dengue vaccine has now been licensed in six countries. We propose that
this live attenuated vaccine acts like a silent natural infection in priming or boosting host …

Dengue vaccine development has reached a major milestone with the initiation, in 2010, of
the first phase III clinical trial to investigate the Sanofi Pasteur CYD tetravalent dengue …

Dengue virus (DENV) is a human pathogen with a large impact on public health. Although
no vaccine against DENV is currently licensed, a recombinant vaccine—chimeric yellow …

Sanofi Pasteur has developed a recombinant, live-attenuated, tetravalent dengue vaccine
(CYD-TDV) that is in late-stage development. The present review summarizes the different …

Background Dengue virus is the most serious mosquito-borne viral threat to public health
and no vaccines or antiviral therapies are approved for dengue fever. The tetravalent …

Dengue has become the most rapidly expanding mosquito-borne infectious disease on the
planet, surpassing malaria and infecting at least 390 million people per year. There is no …